Insulet stock holds steady as analysts see limited upside after recent earnings

Published on 09/09/2026 at 16:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Insulet stock trades near its recent level as of September 9, 2026, after the company’s latest quarterly results showed double digit revenue growth. Analyst data point to an average target price of USD 195.40 and a Hold consensus for Insulet stock.

Flatlay Insulet – Aktienzertifikat, ISIN-Karte US45784P1012, Pod-Gerät und Stethoskop auf Marmor — Insulet Aktien-Flatlay auf weißem Marmor mit Börsenzertifikat, ISIN-Karte US45784P1012, Insulin-Pod und Stethoskop, Illustration mit AI erstellt.

Insulet Corporation stock (ISIN US45784P1012) is trading near its recent level on Nasdaq as of September 9, 2026, after the diabetes technology company reported solid revenue growth and remained under a cautious Hold consensus among Wall Street analysts.

Recent analyst view and valuation

According to MarketBeat on September 9, 2026, fourteen analysts currently rate Insulet stock Buy, eleven have a Hold rating and two recommend Sell, resulting in an overall average rating of Hold and an average target price of USD 195.40.

This implies only a moderate upside versus the latest trading levels and reflects a market that acknowledges Insulet’s revenue and margin strengths while also pricing in execution and competition risks in insulin delivery systems.

Latest reported figures support growth story

In its most recent quarterly report for the second quarter of 2026, Insulet reported revenue growth in the low double digit percent range year over year, driven primarily by continued adoption of its Omnipod insulin delivery platform; revenue for Q2 2026 exceeded the prior year quarter by more than 10 percent and reached several hundred million dollars, according to the company’s earnings release available via Insulet.

Insulet also reported positive operating leverage in Q2 2026, with operating margin expanding by several percentage points versus Q2 2025, as higher volumes and manufacturing efficiencies offset increased research and development spending, based on figures in the same earnings materials from Insulet.

Net income for Q2 2026 improved compared with the prior year quarter as well, with earnings per share rising by a mid-teens percent range versus Q2 2025, reflecting both higher revenue and better cost discipline as described in the company’s latest quarterly report from Insulet.

Risk factors around competition and valuation

For investors, one key risk is that the current average target price of USD 195.40 leaves only limited upside from recent trading levels, suggesting that much of the near term growth story may already be reflected in the valuation, according to the analyst consensus data compiled by MarketBeat.

Another factor to watch is competitive pressure in diabetes care, where larger medical device and pharmaceutical companies continue to invest heavily in insulin pumps and continuous glucose monitoring, potentially challenging Insulet’s market share in its core Omnipod franchise; the company’s Q2 2026 commentary highlights both opportunities and the need for ongoing innovation to sustain growth, as outlined in earnings materials on Insulet.

Stock price and trading metrics

As of September 8, 2026, Insulet stock closed on Nasdaq at a level in the mid USD 180 range, with a daily move of only a few percent versus the prior close and trading volume in the low hundreds of thousands of shares; this places the stock within a 52 week trading band spanning roughly USD 140 at the low end to about USD 230 at the high, and corresponds to a market capitalization in the mid single digit billions of USD, based on recent Nasdaq price data.